Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 549-556

  Greene, Shawna N ^a   Ramos Vara, José A ^a   Craig, Bruce A ^b   Hooser, Steven B ^a   Anderson, Cheryl ^a   Fourez, Lindsey M ^a   Johnson, Brenda M ^a   Stewart, Jane C ^a   Knapp, Deborah W ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Cisplatin; Cox 2 inhibitor; Cyclooxygenase inhibitor; Renal toxicity

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CISPLATIN; CREATININE; PIROXICAM; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CREATININE BLOOD LEVEL; DRUG EFFECT; HISTOPATHOLOGY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS; ANIMAL; ANIMAL BEHAVIOR; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; KIDNEY DISEASE; PILOT STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEHAVIOR, ANIMAL; CISPLATIN; CREATININE; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY DISEASES; MALE; PILOT PROJECTS; PIROXICAM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 75549088537     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1061-2     Document Type: Article

References (30)

1. J Bellmunt S Albiol 2007 Chemotherapy for metastatic or unresectable bladder cancer Semin Oncol 34 135 144 10.1053/j.seminoncol.2006.12.008 1:CAS:528:DC%2BD2sXltlSgsbk%3D 17382797 (Pubitemid 46436117)
2. CN Sternberg SM Donat J Bellmunt, et al. 2007 Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 696 62 79 10.1016/j.urology.2006.10.041
3. DW Knapp NW Glickman WR Widmer, et al. 2000 Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer Cancer Chemother Pharmacol 46 221 226 10.1007/s002800000147 1:CAS:528:DC%2BD3cXlvFOqsbo%3D 11021739 (Pubitemid 30728656)
4. Knapp DW (2006) Animal models: naturally occurring canine urinary bladder cancer. In: Lerner SP, Schoenberg MP, Sternberg CN (eds) Textbook of bladder cancer. Taylor & Francis, Oxon, pp 171-175
5. G Daugaard 1990 Cisplatin nephrotoxicity: experimental and clinical studies Dan Med Bull 37 1 12 1:STN:280:DyaK3c7otlCrsQ%3D%3D 2178884
6. AJ Anand B Bashey 1993 Newer insights into cisplatin nephrotoxicity Ann Pharmacother 27 1519 1525 1:STN:280:DyaK2c7jvVWnsw%3D%3D 8305788
7. K Tsuruya T Ninomiya M Tokumoto, et al. 2003 Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death Kidney Int 63 72 82 10.1046/j.1523-1755.2003.00709.x 1:CAS:528: DC%2BD3sXmtV2itw%3D%3D 12472770 (Pubitemid 35463908)
8. D Sheikh-Hamad W Cacini AR Buckley, et al. 2004 Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney Arch Toxicol 78 147 155 10.1007/s00204-003-0521-4 1:CAS:528:DC%2BD2cXitFCmsrY%3D 14551673 (Pubitemid 38657196)
9. KN Khan CM Venturini RT Bunch, et al. 1998 Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity Toxicol Pathol 26 612 620 1:CAS:528:DyaK1cXmvVSls7o%3D 9789947
10. A Whelton 1999 Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications Am J Med 106 13S 24S 10.1016/S0002-9343(99)00113-8 1:CAS:528:DyaK1MXjvFOns74%3D 10390124 (Pubitemid 29268660)
11. M Bosch-Marce J Claria E Titos, et al. 1999 Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites Gastroenterology 116 1167 1175 10.1016/S0016-5085(99)70020-X 1:CAS:528:DyaK1MXjtVGisb0%3D 10220509 (Pubitemid 29203027)
12. KN Khan SK Paulson KM Verburg, et al. 2002 Pharmacology of cyclooxygenase-2 inhibition in the kidney Kidney Int 61 1210 1219 10.1046/j.1523-1755.2002.00263.x 1:CAS:528:DC%2BD38XjtVGqsbs%3D 11918727 (Pubitemid 34304481)
13. K Hocherl MC Kammerl K Schmuacher, et al. 2002 Role of prostanoids in regulation of the rennin-angiotensin-aldosterone system by salt intake Am J Physio Renal Physiol 283 F294 F301 1:CAS:528:DC%2BD38XmslShtLc%3D
14. M Lopez-Parra J Claria A Planaguma E Titos, et al. 2002 Cyclooxygenase-1 derived prostaglandins are envolved in the maintenance of renal function in rats with cirrhosis and ascites Brit J Pharmacol 135 891 900 10.1038/sj.bjp.0704528 1:CAS:528:DC%2BD38Xit1CntLg%3D
15. SI Mohammed DW Knapp DG Bostwick, et al. 1999 Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder Cancer Res 59 5647 5650 1:CAS:528:DyaK1MXnslyhtr0%3D 10582676
16. KN Khan DW Knapp DB Denicola RK Harris 2000 Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs Am J Vet Res 61 478 481 10.2460/ajvr.2000.61.478 1:CAS:528:DC%2BD3cXjsFCgur4%3D 10803639
17. Y Mizutani H Nakanishi YN Li, et al. 2004 Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522 J Urol 172 1474 1479 10.1097/01.ju.0000131945.74377.ad 1:CAS:528:DC%2BD2cXnsFejsbs%3D 15371874 (Pubitemid 39249752)
18. DC Dobyan J Levi C Jacobs, et al. 1980 Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations J Pharmacol Exp Ther 213 551 556 1:CAS:528:DyaL3cXktF2gur4%3D 7193726
19. F Ries J Klastersky 1986 Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity Am J Kidney Dis 8 368 379 1:CAS:528:DyaL2sXltVylsbg%3D 3538860
20. H Zhou A Kato H Yasuda M Odamaki H Itoh A Hishida 2003 The induction of heat shock protein-72 attenuates cisplatin-induced acute renal failure in rats Pflugers Archiv Eur J Physiol 446 116 124 1:CAS:528:DC%2BD3sXksVKru7c%3D
21. JL Masferrer A Koki K Seibert 1999 Cox-2 inhibitors. A new class of antiangiogenic agents Ann NY Acad Sci 889 84 86 10.1111/j.1749-6632.1999. tb08726.x 1:CAS:528:DC%2BD3cXnt1Smsg%3D%3D 10668485
22. I Tegeder E Neiderberger G Vetter, et al. 2001 Effects of selective cox-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E2 release in the spinal cord J Neurochem 79 777 786 10.1046/j.1471-4159.2001. 00613.x 1:CAS:528:DC%2BD3MXosl2ksL0%3D 11723170 (Pubitemid 33086515)
23. Y-H Zhang J Lu JK Elmquist CB Saper 2003 Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide-induced fever and fos expression in rat brain J Comp Neurol 463 3 12 10.1002/cne.10743 1:CAS:528:DC%2BD3sXmsFCgt7k%3D 12811798 (Pubitemid 36835409)
24. S Chopra JS Kaufman TW Jones, et al. 1982 Cis-diamminedichlorplatinum- induced acute renal failure in the rat Kidney Int 21 54 64 10.1038/ki.1982.8 1:CAS:528:DyaL38XhsFGitr8%3D 7200546
25. CA Ecelbarger JM Sands JJ Doran, et al. 2001 Expression of salt and urea transporters in rat kidney during cisplatin-induced polyuria Kidney Int 60 2274 2282 10.1046/j.1523-1755.2001.00048.x 1:CAS:528:DC%2BD3MXpt1KjsLw%3D 11737600 (Pubitemid 33070469)
26. NM Osman MP Copley CL Litterst 1984 Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats Cancer Chemother Pharmacol 13 58 62 10.1007/BF00401449 1:CAS:528: DyaL2cXltVektrs%3D 6428763
27. Q Huang RT Dunn II S Jayadev O DiSorbo, et al. 2001 Assessment of cisplatin-induced nephrotoxicity by microarray technology Toxicol Sci 63 196 207 10.1093/toxsci/63.2.196 1:CAS:528:DC%2BD3MXns1Ggurc%3D 11568363 (Pubitemid 32982793)
28. M Rooseboom G Schaaf JN Commandeur, et al. 2002 Beta-lyase-dependent attenuation of cisplatin-mediated toxicity by selenocysteine Se-conjugates in renal tubular cell lines J Pharmacol Exp Ther 301 884 892 10.1124/jpet.301.3.884 1:CAS:528:DC%2BD38XktlGjs78%3D 12023515 (Pubitemid 34595076)
29. RC Harris 2006 COX-2 and the kidney J Cardiovas Pharmacol 47 S37 S42 10.1097/00005344-200605001-00007 1:CAS:528:DC%2BD28XlvV2nsro%3D (Pubitemid 44651783)
30. V Launay-Vacher JB Rey C Isnard-Bagnis, et al. 2008 European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care Cancer Chemother Pharmacol 61 903 909 10.1007/s00280-008-0711-0 1:CAS:528:DC%2BD1cXjsF2gsL8%3D 18317762